Prelude Therapeutics Q3 net loss narrows

Prelude Therapeutics Incorporated

12/11/2025 12:12

Overview

Prelude Q3 2025 net loss narrows to $19.7 mln from $32.3 mln year-over-year

Company reports cash runway into 2027 after receiving $60 mln from Incyte

Lead candidates from JAK2V617F and KAT6A programs advancing to clinical trials

Outlook

Prelude anticipates filing IND for JAK2V617F inhibitor in first half of 2026

Company expects cash runway to extend into 2027

Prelude plans IND filing for KAT6A degrader program by mid-2026

Result Drivers

JAK2V617F PROGRAM - Lead candidate advancing with IND filing expected in Q1 2026, targeting mutation in myeloproliferative neoplasms

KAT6A PROGRAM - Lead candidate advancing with IND filing expected in mid-2026, focusing on ER+ breast cancer

DAC COLLABORATION - Expanded scope with AbCellera Biologics, enabling use of degrader payloads on additional targets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.26
Q3 Net Income
-$19.73 mln
Q3 Income from Operations
-$20.42 mln
Q3 Operating Expenses
$26.92 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.00, about 66.3% above its November 11 closing price of $1.35

Press Release: ID:nGNX8bLPwy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)